Latest Checkpoint Capital L.P. Stock Portfolio
Checkpoint Capital L.P. Performance:
2024 Q3: 12.64%YTD: 10.74%
Performance for 2024 Q3 is 12.64%, and YTD is 10.74%.
About Checkpoint Capital L.P. and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Checkpoint Capital L.P. reported an equity portfolio of $201.6 Millions as of 30 Sep, 2024.
The top stock holdings of Checkpoint Capital L.P. are , RYTM, PHAT. The fund has invested 24.9% of it's portfolio in ARGENX SE and 17.2% of portfolio in RHYTHM PHARMACEUTICALS INC.
The fund managers got completely rid off CORCEPT THERAPEUTICS INC (CORT), KYMERA THERAPEUTICS INC (KYMR) and APPLIED THERAPEUTICS INC (APLT) stocks. They significantly reduced their stock positions in TREVI THERAPEUTICS INC (TRVI), PROTAGONIST THERAPEUTICS INC (PTGX) and RHYTHM PHARMACEUTICALS INC (RYTM). Checkpoint Capital L.P. opened new stock positions in TSCAN THERAPEUTICS INC (TCRX), STOKE THERAPEUTICS INC (STOK) and DISC MEDICINE INC. The fund showed a lot of confidence in some stocks as they added substantially to SOLENO THERAPEUTICS INC (SLNO), CYTOKINETICS INC (CYTK) and PHATHOM PHARMACEUTICALS INC (PHAT).
The top stock holdings of Checkpoint Capital L.P. are , RYTM, PHAT. The fund has invested 24.9% of it's portfolio in ARGENX SE and 17.2% of portfolio in RHYTHM PHARMACEUTICALS INC.
The fund managers got completely rid off CORCEPT THERAPEUTICS INC (CORT), KYMERA THERAPEUTICS INC (KYMR) and APPLIED THERAPEUTICS INC (APLT) stocks. They significantly reduced their stock positions in TREVI THERAPEUTICS INC (TRVI), PROTAGONIST THERAPEUTICS INC (PTGX) and RHYTHM PHARMACEUTICALS INC (RYTM). Checkpoint Capital L.P. opened new stock positions in TSCAN THERAPEUTICS INC (TCRX), STOKE THERAPEUTICS INC (STOK) and DISC MEDICINE INC. The fund showed a lot of confidence in some stocks as they added substantially to SOLENO THERAPEUTICS INC (SLNO), CYTOKINETICS INC (CYTK) and PHATHOM PHARMACEUTICALS INC (PHAT).
Checkpoint Capital L.P. Annual Return Estimates Vs S&P 500
Our best estimate is that Checkpoint Capital L.P. made a return of 12.64% in the last quarter. In trailing 12 months, it's portfolio return was 52.76%.
New Buys
| Ticker | $ Bought |
|---|---|
| tscan therapeutics inc | 4,110,200 |
| stoke therapeutics inc | 1,935,850 |
| disc medicine inc | 1,255,180 |
New stocks bought by Checkpoint Capital L.P.
Additions
| Ticker | % Inc. |
|---|---|
| soleno therapeutics inc | 194 |
| cytokinetics inc | 145 |
| phathom pharmaceuticals inc | 71.92 |
| pliant therapeutics inc | 63.65 |
| cidara therapeutics inc | 25.45 |
| argenx se | 12.6 |
Additions to existing portfolio by Checkpoint Capital L.P.
Reductions
| Ticker | % Reduced |
|---|---|
| trevi therapeutics inc | -50.01 |
| protagonist therapeutics inc | -32.39 |
| rhythm pharmaceuticals inc | -28.06 |
| axsome therapeutics inc | -27.91 |
| atyr pharma inc | -10.79 |
| avadel pharmaceuticals plc | -3.35 |
Checkpoint Capital L.P. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| corcept therapeutics inc | -7,951,930 |
| applied therapeutics inc | -1,062,280 |
| kymera therapeutics inc | -2,447,700 |
Checkpoint Capital L.P. got rid off the above stocks
Sector Distribution
Checkpoint Capital L.P. has about 67.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 67.3 |
| Others | 32.7 |
Market Cap. Distribution
Checkpoint Capital L.P. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 44.2 |
| UNALLOCATED | 32.7 |
| SMALL-CAP | 20.1 |
| MICRO-CAP | 3.1 |
Stocks belong to which Index?
About 61.4% of the stocks held by Checkpoint Capital L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 61.4 |
| Others | 38.6 |
Checkpoint Capital L.P. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Checkpoint Capital L.P.
Checkpoint Capital L.P. has 16 stocks in it's portfolio. About 95.4% of the portfolio is in top 10 stocks. CYTK proved to be the most loss making stock for the portfolio. PHAT was the most profitable stock for Checkpoint Capital L.P. last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALLK | allakos inc | 0.21 | 649,957 | 424,552 | unchanged | 0.00 | ||
| APLT | applied therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AXSM | axsome therapeutics inc | 9.35 | 209,632 | 18,839,600 | reduced | -27.91 | ||
| CDTX | cidara therapeutics inc | 0.97 | 182,426 | 1,961,080 | added | 25.45 | ||
| CORT | corcept therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CYTK | cytokinetics inc | 12.23 | 466,813 | 24,647,700 | added | 145 | ||
| KYMR | kymera therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| LIFE | atyr pharma inc | 1.52 | 1,736,480 | 3,056,200 | reduced | -10.79 | ||
| PHAT | phathom pharmaceuticals inc | 13.49 | 1,504,310 | 27,197,900 | added | 71.92 | ||
| PLRX | pliant therapeutics inc | 2.11 | 380,000 | 4,259,800 | added | 63.65 | ||
| PTGX | protagonist therapeutics inc | 5.36 | 240,000 | 10,800,000 | reduced | -32.39 | ||
| RYTM | rhythm pharmaceuticals inc | 17.24 | 663,381 | 34,754,500 | reduced | -28.06 | ||
| SLNO | soleno therapeutics inc | 1.45 | 57,983 | 2,927,560 | added | 194 | ||
| STOK | stoke therapeutics inc | 0.96 | 157,514 | 1,935,850 | new | |||
| TCRX | tscan therapeutics inc | 2.04 | 825,341 | 4,110,200 | new | |||
| TRVI | trevi therapeutics inc | 0.41 | 250,000 | 835,000 | reduced | -50.01 | ||
| argenx se | 24.88 | 92,500 | 50,142,400 | added | 12.6 | |||
| avadel pharmaceuticals plc | 7.16 | 1,100,000 | 14,426,500 | reduced | -3.35 | |||
| disc medicine inc | 0.62 | 25,543 | 1,255,180 | new | ||||